拨康视云－Ｂ(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02592 拨康视云－Ｂ

休市中 07-11 16:08:03

5.720

-0.080

-1.38%

最高5.900	最低5.700	成交量89.70万
今开5.800	昨收5.800	日振幅3.45%
总市值47.98亿	流通市值47.98亿	总股本8.39亿
成交额515.45万	换手率0.11%	流通股本8.39亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"拨康视云－Ｂ","latestPrice":5.72,"timestamp":1752221283030,"preClose":5.8,"halted":0,"volume":897000,"delay":0,"floatShares":838892874,"shares":838892874,"eps":-1.6368638779210787,"marketStatus":"休市中","change":-0.08,"latestTime":"07-11 16:08:03","open":5.8,"high":5.9,"low":5.7,"amount":5154495,"amplitude":0.034483,"askPrice":5.72,"askSize":3000,"bidPrice":5.7,"bidSize":83500,"shortable":0,"etf":0,"ttmEps":-1.6368638779210787,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752456600000},"marketStatusCode":7,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":5.8,"openAndCloseTimeList":[[1752197400000,1752206400000],[1752210000000,1752220800000]],"volumeRatio":0.319029093102516,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02592","defaultTab":"news","newsList":[{"id":"2550261737","title":"拨康视云-B07月10日主力净流出66.7万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2550261737","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550261737?lang=zh_cn&edition=full","pubTime":"2025-07-10 16:15","pubTimestamp":1752135340,"startTime":"0","endTime":"0","summary":"07月10日, 拨康视云-B股价跌1.53%，报收5.80元，成交金额659.3万元，换手率0.14%，振幅3.06%，量比0.10。拨康视云-B今日主力资金净流出66.7万元，上一交易日主力净流入24.9万元。该股近5个交易日下跌6.45%，主力资金累计净流出299.8万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出299.8万元，其中净流出天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710165629a4422ff2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710165629a4422ff2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":1},{"id":"2549539224","title":"近期国内融资|泰德医药、拨康视云港交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2549539224","media":"药菓","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549539224?lang=zh_cn&edition=full","pubTime":"2025-07-07 18:01","pubTimestamp":1751882490,"startTime":"0","endTime":"0","summary":"公司致力于开发新一代治疗性和诊断用抗体药物，通过自主研发的智能抗体技术，能够高效设计并生成满足临床需求的抗体，同时显著降低治疗性抗体的开发成本。禾元生物成立于2006年，以植物表达动物蛋白的方式，生产药品、药用辅料及科研试剂。这也是重启科创板第五套上市标准后，首家按此标准成功过会的IPO企业。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191409a43bbb36&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707191409a43bbb36&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","03880"],"gpt_icon":1},{"id":"2549058684","title":"6家创新药新锐公司完成新一轮融资！有3家来自中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2549058684","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549058684?lang=zh_cn&edition=full","pubTime":"2025-07-07 15:30","pubTimestamp":1751873423,"startTime":"0","endTime":"0","summary":"根据数据统计，6月30日~7月6日，全球范围内有至少6家致力于创新药研发的新锐公司宣布完成新一轮融资，包括麦科奥特、拨康视云等。业内表示，这些创新药研发新锐公司的融资进展，不仅为各自的研发项目和商业化进程提供了有力的资金支持，也将推动全球创新药研发行业的进一步发展，为各类疾病的治疗带来新的希望。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707153403953941d3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250707153403953941d3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","06978","02592","BK1574"],"gpt_icon":1},{"id":"2549316281","title":"四战IPO，这家眼科新贵成功上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2549316281","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549316281?lang=zh_cn&edition=full","pubTime":"2025-07-05 07:31","pubTimestamp":1751671895,"startTime":"0","endTime":"0","summary":"在此之前，拨康视云曾四次向港交所递交上市申请，最终成功上市。经营层面面临的挑战，尤其是持续的财务亏损及收入匮乏，成为其上市之路历经波折的关键因素之一。而与参天制药的战略合作，则被视作推动其成功上市的重要催化剂。目前，全球尚未有专门用于治疗翼状胬肉的药物。小结整体来看，拨康视云的短期价值主要建立在CBT-001的成功之上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705073519a72f8a41&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250705073519a72f8a41&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":1},{"id":"2548615973","title":"拨康视云-B07月04日主力净流出237.9万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2548615973","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548615973?lang=zh_cn&edition=full","pubTime":"2025-07-04 16:15","pubTimestamp":1751616909,"startTime":"0","endTime":"0","summary":"07月04日, 拨康视云-B股价跌5.48%，报收5.86元，成交金额4443.2万元，换手率0.86%，振幅14.84%，量比0.00。该股近5个交易日下跌41.98%，主力资金累计净流出237.9万元；近20日主力资金累计净流出237.9万元，其中净流出天数为1日。|07月04日主力加仓幅度排名||#|股票简称|主力净额占比|#|环球战略集团股权|8.77%|#|高地股份|3.66%|#|吉宏股份|2.34%|#|...|...|#2538|拨康视云-B|-0.05%|（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704165307a72e7758&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704165307a72e7758&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":0},{"id":"1111120890","title":"异动解读 | 拨康视云-B盘中大跌6.45%，上市后持续下跌，较发行价已跌超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111120890","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111120890?lang=zh_cn&edition=full","pubTime":"2025-07-04 15:02","pubTimestamp":1751612554,"startTime":"0","endTime":"0","summary":"港股市场上，拨康视云-B今日盘中大跌6.45%，延续了上市以来的跌势。截至盘中，该股报5.81港元，成交额达3729.14万港元。值得注意的是，这已是该股上市后的第二个交易日，而其股价较招股价已累计下跌超过42%，引发市场关注。其中，公司拥有两款核心产品CBT-001和CBT-009，均为自主开发。尽管拨康视云-B在眼科药物研发领域展现出潜力，但其上市后的持续下跌反映出投资者对该股的谨慎态度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":1},{"id":"1109428087","title":"异动解读 | 拨康视云-B盘中大跌6.45%，上市次日较招股价已跌超42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1109428087","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109428087?lang=zh_cn&edition=full","pubTime":"2025-07-04 15:02","pubTimestamp":1751612543,"startTime":"0","endTime":"0","summary":"拨康视云-B今日盘中大跌6.45%，延续上市首日的跌势。截至下午2点55分，该股报5.81港元，成交额达3729.14万港元。值得注意的是，与招股价相比，拨康视云-B的股价已累计下跌超过42%，引发市场关注。根据公司招股书显示，拨康视云-B拥有两款核心产品CBT-001和CBT-009。其中，CBT-001用于治疗翼状胬肉，公司已分别于2022年6月和2023年9月在美国和中国启动第3期多地区临床试验。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":1},{"id":"2548352951","title":"【港股异动 | 拨康视云-B(02592.HK)上市次日再跌6% 较招股价已跌42% 公司专注眼科创新药物研发】智通财经","url":"https://stock-news.laohu8.com/highlight/detail?id=2548352951","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548352951?lang=zh_cn&edition=full","pubTime":"2025-07-04 14:55","pubTimestamp":1751612103,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06978","02592","BK1161","159992","BK1574"],"gpt_icon":0},{"id":"2548389651","title":"正大天晴重组人凝血因子VIIa获批上市；拨康视云上市首日破发","url":"https://stock-news.laohu8.com/highlight/detail?id=2548389651","media":"氨基观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548389651?lang=zh_cn&edition=full","pubTime":"2025-07-03 19:09","pubTimestamp":1751540990,"startTime":"0","endTime":"0","summary":"正大天晴又有新收获。7月3日，创新药企拨康视云港股上市。二级市场方面，公司表现不佳，上市首日破发，大跌38.61%。9）正大天晴重组人凝血因子VIIa获批上市7月3日，据NMPA官网，正大天晴的注射用重组人凝血因子VIIa已获批上市，适应症为抑制物阳性先天性血友病A或B患者以及某些特定类型罕见出血性疾病患者群体出血的治疗和外科手术或有创操作出血的防治。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703191301a72ca04f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703191301a72ca04f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592"],"gpt_icon":1},{"id":"2548896683","title":"手握2款3期新药，眼科明星Biotech港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548896683","media":"动脉新医药","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548896683?lang=zh_cn&edition=full","pubTime":"2025-07-03 19:05","pubTimestamp":1751540741,"startTime":"0","endTime":"0","summary":"7月3日，“眼科创新药新锐”Cloudbreak Pharma Inc.拨康视云在港交所正式上市。其全球治疗药物市场规模预计将于2027年达到2.73亿美元、2032年达到25.29亿美元，复合年增长率为56.0%。因此，CBT-001有望成为治疗翼状胬肉的全球首创药物，享有先发优势。弗若斯特沙利文报告显示，全球治疗青少年近视药物的市场规模由2018年的7230万美元增加至2022年的8400万美元，复合年增长率为3.8%。2022年，全球睑板腺功能异常相关的干眼症患者人数将达到9.232亿人。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703190942a4cd3dcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703190942a4cd3dcc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02592","07226","HSTECH","HSCEI"],"gpt_icon":1},{"id":"2548708798","title":"拨康视云正式上市 百惠担任联席账簿管理人及联席牵头经办人","url":"https://stock-news.laohu8.com/highlight/detail?id=2548708798","media":"中宏网官微","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548708798?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:27","pubTimestamp":1751531220,"startTime":"0","endTime":"0","summary":"，正式登陆香港联交所主板，每股定价为10.10港元，录得近78倍超额认购，百惠金控团队担任联席账簿管理人及联席牵头经办人。　　作为本次 IPO 项目的联席账簿管理人及联席牵头经办人，百惠金控团队充分调动自身广泛的市场资源，为拨康视云提供全周期上市解决方案。同时，旗下的百惠资本持有第六类牌照，并且拥有保荐人资格。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2025-07-03/doc-infeevpi3404944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02592"],"gpt_icon":1},{"id":"2548876896","title":"7月3日拨康视云在港交所上市成为苏州今年以来第5家境外上市企业。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548876896","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548876896?lang=zh_cn&edition=full","pubTime":"2025-07-03 16:13","pubTimestamp":1751530404,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["HEXmain","02592"],"gpt_icon":0},{"id":"2548272098","title":"拨康视云正式登陆港交所，市值近80亿港元，首创新药抢占眼科患者蓝海空白市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2548272098","media":"独角兽早知道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548272098?lang=zh_cn&edition=full","pubTime":"2025-07-03 10:50","pubTimestamp":1751511000,"startTime":"0","endTime":"0","summary":"拨康视云今日开盘报9.50港元/股，市值79.69亿港元。招股书披露，拨康视云是一家临床阶段眼科生物科技公司，致力于开发各种疗法。就核心产品CBT-009而言，拨康视云已考虑适用于近视替代治疗选择的定价。然而，该等手术不适用于18岁以下的患者。2022年度、2023年度及2024年度，拨康视云年内亏损分别约为0.67亿美元、1.29亿美元、0.99亿美元，此外，2024年收益约为1000万美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU3MTY1MzExOQ==&mid=2247597158&idx=2&sn=6828f99b1ad1597f462417c73ebd9699&chksm=fd0b21e75be443d99163d56fc8f7b7cc5f416c7e3dec6b74c31aebc759c6bf3fc68afaa198da&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["06978","BK1161","02592","BK1574"],"gpt_icon":1},{"id":"2548502842","title":"新股首日 | 拨康视云-B跌超16%，公司为临床阶段眼科生物科技公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2548502842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548502842?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:38","pubTimestamp":1751506715,"startTime":"0","endTime":"0","summary":"7月3日，拨康视云-B首日盘初跌超16%，成交额8232万港元。公开资料显示，拨康视云是一间临床阶段眼科生物科技公司，致力于开发各种疗法。集团已经建立一个由候选药物组成的创新管线，覆盖眼睛前部和后部的主要疾病，其中有四款处于临床阶段的候选药物及四款处于临床前阶段的候选药物，管线中的所有候选药物均为自主研发。核心产品CBT-001适用于治疗翼状胬肉，集团分别于2022年6月及2023年9月在美国及中国启动第3期多地区临床试验。","market":"sh","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313367.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0},{"id":"1191258223","title":"异动解读 | 拨康视云-B首日挂牌大跌7.43%，IPO超额认购热情难挽股价下跌","url":"https://stock-news.laohu8.com/highlight/detail?id=1191258223","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191258223?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:32","pubTimestamp":1751506361,"startTime":"0","endTime":"0","summary":"临床阶段眼科生物科技公司拨康视云-B今日在港交所挂牌上市，盘中大跌7.43%，引发市场关注。拨康视云-B此前以每股10.1港元的价格完成全球发售，共发行6058.2万股股份，募集资金净额约5.22亿港元。公司香港公开发售部分获得78.78倍超额认购，显示出投资者的热烈兴趣。然而，这种热情似乎并未延续到二级市场。尽管IPO认购火热，但拨康视云-B上市首日表现不佳可能与多重因素有关。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":0},{"id":"1187279368","title":"异动解读 | 拨康视云-B上市首日盘中大跌7.43%，较招股价跌超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1187279368","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187279368?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:32","pubTimestamp":1751506350,"startTime":"0","endTime":"0","summary":"拨康视云-B今日在港交所主板挂牌上市，盘中大跌7.43%，股价跌至9.35港元，较10.1港元的招股价下跌超过13%，引发市场关注。拨康视云-B是一家临床阶段眼科生物科技公司，致力于开发新型及差异化疗法。然而，该股今日开盘即表现疲软，开盘价为9.5港元，较招股价低5.94%。分析人士指出，尽管公司IPO获得较高认购倍数，但上市首日股价表现不佳，可能反映了投资者对生物科技公司长期盈利能力的担忧，以及当前市场对新股的谨慎态度。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02592"],"gpt_icon":0},{"id":"2548637842","title":"【新股首日 | 拨康视云-B(02592.HK)首挂上市 早盘低开5.94% 公司为临床阶段眼科生物科技公司】智通财经A","url":"https://stock-news.laohu8.com/highlight/detail?id=2548637842","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548637842?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:26","pubTimestamp":1751506009,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["159837","02592"],"gpt_icon":0},{"id":"2548843189","title":"港股IPO动态：今日拨康视云上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548843189","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548843189?lang=zh_cn&edition=full","pubTime":"2025-07-03 06:10","pubTimestamp":1751494244,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1934453819.USD","02651","BK0196","LU1979443071.USD","BK0076","SGXZ49509284.SGD","06613","BK0028","300433","02553","BK0214","02592","02597","SGXZ81163826.USD","BK0201","BK0072","BK0064","02590","01304"],"gpt_icon":0},{"id":"2548381566","title":"港股公告掘金 | 小鹏汽车6月智能电动汽车交付量同比增长224% 拨康视云明日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2548381566","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548381566?lang=zh_cn&edition=full","pubTime":"2025-07-02 22:58","pubTimestamp":1751468287,"startTime":"0","endTime":"0","summary":"【重大事项】拨康视云-B(02592)公开发售获78.78倍认购 全球发售净筹约5.22亿港元首钢朗泽(02553)因民事诉讼将延迟全球发售及上市德林控股(01709)拟携手Asseto在亚洲市场共同探索并开发RWA的代币化解决方案万国数据-SW(09698)：C-REIT的首次公开发售(IPO)的最终发售价为每份额3.00元宜明昂科-B(01541)：IMM2510/AXN-2510获美国FDA","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313300.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4099","BK1575","BK1119","09868","BK4614","BK4551","02603","YANG","07226","HSTECH","BK1137","02592","01045","EVS.SI","LU0593848301.USD","BK1108","BK4505","BK1610","BK4555","XPEV","BK1587","HSCEI","BK4526","BK1539"],"gpt_icon":0},{"id":"2548852894","title":"拨康视云-B(02592)公开发售获78.78倍认购 全球发售净筹约5.22亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548852894","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548852894?lang=zh_cn&edition=full","pubTime":"2025-07-02 20:07","pubTimestamp":1751458071,"startTime":"0","endTime":"0","summary":"智通财经APP讯，拨康视云-B(02592)公布配发结果，公司全球发售6058.2万股股份，香港公开发售占20%，国际发售占80%。最终发售价为每股10.1港元，全球发售净筹约5.22亿港元。每手500股，预期股份将于 2025年7月3日(星期四)上午九时正(香港时间)在联交所开始买卖。其中，香港公开发售获78.78倍认购，国际发售获0.89倍认购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1313222.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02592"],"gpt_icon":0}],"profile":{"websiteUrl":"http://cloudbreakpharma.com","stockEarnings":[{"period":"1week","weight":-0.0239},{"period":"1month","weight":-0.4337},{"period":"ytd","weight":-0.4337}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":-0.0093},{"period":"3month","weight":0.1542},{"period":"6month","weight":0.2662},{"period":"1year","weight":0.3537},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"Cloudbreak Pharma(拨康视云)是一家在临床阶段的眼科药物公司。公司于2015年9月在美国加州尔湾市成立。我们团队拥有多元化的技能和丰富的眼科药物研发经验。\n我们的眼睛不仅仅是视觉工具。我们通过眼睛与周围的人和世界联系和沟通。拨康视云的使命是确保没有人因眼睛健康情况不佳而受到阻碍。我们的目标是通过治疗各种损害视力和生活品质的眼部疾病来帮助人们更好的享受生活。\n我们是一家临床阶段的全球生物技术公司,开发治疗慢性眼病的眼科药物,这些疾病的治疗选择往往很少。我们广泛的产品线是由拥有经验和专业知识的内部科学家开发的,以发现新的有真对性的作用机制和适合局部眼部给药的配方。我们对眼科疾病发病机制的深入了解和广泛的科学知识使我们开发出我们的主要候选产品 CBT-001,这是一种研究阶段滴眼剂治疗方法,有可能减缓或阻止翼状胬肉的进展,翼状胬肉是一种高度诊断不足和治疗不足的疾病, 尚未有获得批准的药物治疗方式。","exchange":"SEHK","name":"拨康视云－Ｂ","nameEN":"CLOUDBREAK-B"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"拨康视云－Ｂ(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供拨康视云－Ｂ(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"拨康视云－Ｂ,02592,拨康视云－Ｂ股票,拨康视云－Ｂ股票老虎,拨康视云－Ｂ股票老虎国际,拨康视云－Ｂ行情,拨康视云－Ｂ股票行情,拨康视云－Ｂ股价,拨康视云－Ｂ股市,拨康视云－Ｂ股票价格,拨康视云－Ｂ股票交易,拨康视云－Ｂ股票购买,拨康视云－Ｂ股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"拨康视云－Ｂ(02592)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供拨康视云－Ｂ(02592)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}